Health & Environmental Research Online (HERO)


Print Feedback Export to File
7231748 
Journal Article 
Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation 
Adeboyeje, G; Sylwestrzak, G; Barron, JJ; White, J; Rosenberg, A; Abarca, J; Crawford, G; Redberg, R; , 
2017 
English 
28854073 
The use of non-vitamin K oral anticoagulants (NOACs) has increased steadily following marketing approval; however, their relative safety in nonvalvular atrial fibrillation (NVAF) patients in real-world clinical practice remains unclear.